WO2009038701A3 - Formulation containing cyclin-dependent kinase inhibiting compound and method of treating tumors using the same - Google Patents

Formulation containing cyclin-dependent kinase inhibiting compound and method of treating tumors using the same Download PDF

Info

Publication number
WO2009038701A3
WO2009038701A3 PCT/US2008/010778 US2008010778W WO2009038701A3 WO 2009038701 A3 WO2009038701 A3 WO 2009038701A3 US 2008010778 W US2008010778 W US 2008010778W WO 2009038701 A3 WO2009038701 A3 WO 2009038701A3
Authority
WO
WIPO (PCT)
Prior art keywords
dependent kinase
formulation containing
treating tumors
same
kinase inhibiting
Prior art date
Application number
PCT/US2008/010778
Other languages
French (fr)
Other versions
WO2009038701A2 (en
Inventor
Valentyn Antochshuk
Rajat Bannerji
Anita Dabbara
Paul Kirschmeier
David A. Parry
Mohammed Shameem
Paul Statkevich
Siu-Long Yao
Original Assignee
Schering Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corporation filed Critical Schering Corporation
Priority to EP08831837A priority Critical patent/EP2200584A2/en
Priority to MX2010002927A priority patent/MX2010002927A/en
Priority to AU2008301925A priority patent/AU2008301925A1/en
Priority to US12/678,320 priority patent/US20100286038A1/en
Priority to NZ584037A priority patent/NZ584037A/en
Priority to CN200880116604A priority patent/CN101854915A/en
Priority to CA2699761A priority patent/CA2699761A1/en
Priority to BRPI0816823A priority patent/BRPI0816823A8/en
Priority to JP2010524891A priority patent/JP2010539173A/en
Publication of WO2009038701A2 publication Critical patent/WO2009038701A2/en
Publication of WO2009038701A3 publication Critical patent/WO2009038701A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

This application discloses a novel formulation containing a 3-amino-4-sub stituted pyrazole derivative which has cyclin-dependent kinase inhibiting properties, and a method of treating tumors using the novel formulation.
PCT/US2008/010778 2007-09-17 2008-09-16 Formulation containing cyclin-dependent kinase inhibiting compound and method of treating tumors using the same WO2009038701A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
EP08831837A EP2200584A2 (en) 2007-09-17 2008-09-16 Formulation containing cyclin-dependent kinase inhibiting compound and method of treating tumors using the same
MX2010002927A MX2010002927A (en) 2007-09-17 2008-09-16 Formulation containing cyclin-dependent kinase inhibiting compound and method of treating tumors using the same.
AU2008301925A AU2008301925A1 (en) 2007-09-17 2008-09-16 Formulation containing cyclin-dependent kinase inhibiting compound and method of treating tumors using the same
US12/678,320 US20100286038A1 (en) 2007-09-21 2008-09-16 Formulation containing cyclin-dependent kinase inhibiting compound and method of treating tumors using the same
NZ584037A NZ584037A (en) 2007-09-17 2008-09-16 Formulation containing cyclin-dependent kinase inhibiting compound and method of treating tumors using the same
CN200880116604A CN101854915A (en) 2007-09-17 2008-09-16 Formulation containing cyclin-dependent kinase inhibiting compound and method of treating tumors using the same
CA2699761A CA2699761A1 (en) 2007-09-17 2008-09-16 Formulation containing cyclin-dependent kinase inhibiting compound and method of treating tumors using the same
BRPI0816823A BRPI0816823A8 (en) 2007-09-17 2008-09-16 FORMULATION CONTAINING CYCLIN-DEPENDENT KINASE INHIBITOR COMPOUND AND TUMOR TREATMENT METHOD USING IT
JP2010524891A JP2010539173A (en) 2007-09-17 2008-09-16 Formulations containing cyclin-dependent kinase inhibitor compounds and methods of treating tumors using this formulation

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US99418507P 2007-09-17 2007-09-17
US60/994,185 2007-09-17
US99946907P 2007-10-17 2007-10-17
US60/999,469 2007-10-17
US5378408P 2008-05-16 2008-05-16
US61/053,784 2008-05-16

Publications (2)

Publication Number Publication Date
WO2009038701A2 WO2009038701A2 (en) 2009-03-26
WO2009038701A3 true WO2009038701A3 (en) 2009-09-11

Family

ID=40020243

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/010778 WO2009038701A2 (en) 2007-09-17 2008-09-16 Formulation containing cyclin-dependent kinase inhibiting compound and method of treating tumors using the same

Country Status (12)

Country Link
EP (1) EP2200584A2 (en)
JP (1) JP2010539173A (en)
KR (1) KR20100072253A (en)
CN (1) CN101854915A (en)
AU (1) AU2008301925A1 (en)
BR (1) BRPI0816823A8 (en)
CA (1) CA2699761A1 (en)
CO (1) CO6270205A2 (en)
MX (1) MX2010002927A (en)
NZ (1) NZ584037A (en)
SG (1) SG184760A1 (en)
WO (1) WO2009038701A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012061551A1 (en) * 2010-11-05 2012-05-10 Millennium Pharmaceuticals, Inc. Administration of nedd8-activating enzyme inhibitor
TWI632921B (en) * 2011-10-19 2018-08-21 大塚製藥股份有限公司 Solution for oral administration
KR102232153B1 (en) 2013-08-20 2021-03-24 머크 샤프 앤드 돔 코포레이션 Treating cancer with a combination of a pd-1 antagonist and dinaciclib

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040209878A1 (en) * 2002-09-04 2004-10-21 Schering Corporation And Pharmacopeia, Inc. Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
US20080050384A1 (en) * 2002-09-04 2008-02-28 Shering Corporation And Pharmacopeia, Inc. Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040209878A1 (en) * 2002-09-04 2004-10-21 Schering Corporation And Pharmacopeia, Inc. Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
US20080050384A1 (en) * 2002-09-04 2008-02-28 Shering Corporation And Pharmacopeia, Inc. Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
WO2008130570A1 (en) * 2007-04-20 2008-10-30 Schering Corporation Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors

Also Published As

Publication number Publication date
CO6270205A2 (en) 2011-04-20
MX2010002927A (en) 2010-06-01
CA2699761A1 (en) 2009-03-26
BRPI0816823A8 (en) 2016-02-10
SG184760A1 (en) 2012-10-30
BRPI0816823A2 (en) 2015-03-10
WO2009038701A2 (en) 2009-03-26
CN101854915A (en) 2010-10-06
JP2010539173A (en) 2010-12-16
NZ584037A (en) 2012-08-31
EP2200584A2 (en) 2010-06-30
KR20100072253A (en) 2010-06-30
AU2008301925A1 (en) 2009-03-26

Similar Documents

Publication Publication Date Title
EP3672973A4 (en) Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
EP3797109A4 (en) Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
EP3608321A4 (en) 1h-imidazo[4,5-h]quinazoline compound as protein kinase inhibitor
WO2007059202A3 (en) Pyrazolyl urea derivatives useful in the treatment of cancer
EP2057158B8 (en) Triazole derivatives as kinase inhibitors
WO2011031896A3 (en) Pi3 kinase inhibitors and uses thereof
MY146989A (en) Kinase inhibitors
WO2009006389A3 (en) Pyrimidine derivatives useful as raf kinase inhibitors
WO2008128072A3 (en) Axl kinase inhibitors useful for the treatment of cancer or hyperproliferative disorders
WO2007079164A3 (en) Protein kinase inhibitors
WO2010002655A3 (en) Pyrimidine derivatives as kinase inhibitors
WO2007041358A8 (en) Substituted pyrazole compounds
IL199323A (en) Substituted pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
IL197933A (en) Kinase inhibitors, pharmaceutical compositions comprising such compounds and uses thereof
WO2007087245A3 (en) Ret tyrosine kinase inhibition
SI2120932T1 (en) Indazole derivatives as kinase inhibitors for the treatment of cancer
IL202505A (en) 2-oxo-3-benzyl-benzoxazol-2-one derivatives and related compounds as met kinase inhibitors for the treatment of tumors, medicaments comprising them and use thereof
MX2009006535A (en) Indol-4-yl-pyrimidinyl-2-yl-amine derivatives and use thereof as cyclin dependant kinase inhibitors.
WO2007117995A3 (en) Kinase inhibitors
WO2007106436A3 (en) Photoactive compounds and compositions and uses thereof
IL201064A0 (en) Janus kinase inhibitor compounds, compositions comprising the same and uses thereof
TN2011000207A1 (en) Akt and p70 s6 kinase inhibitors
EP3418275A4 (en) Novel 2,3,5-substituted thiophene compound as protein kinase inhibitor
WO2011028044A3 (en) Pyrazole derivatives, preparation method thereof, and composition for prevention and treatment of osteoporosis containing same
WO2011028043A3 (en) Pyrazole derivatives, preparation method thereof, and composition for prevention and treatment of osteoporosis containing same

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880116604.5

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08831837

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2008301925

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1459/CHENP/2010

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2010524891

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2699761

Country of ref document: CA

Ref document number: 12010500573

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 584037

Country of ref document: NZ

Ref document number: MX/A/2010/002927

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 10035469

Country of ref document: CO

ENP Entry into the national phase

Ref document number: 2008301925

Country of ref document: AU

Date of ref document: 20080916

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20107008144

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2008831837

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12678320

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0816823

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20100317